Antengene scores $97m Series C
Antengene Corporation, a hematology and oncology-focused biopharmaceutical company, has raised $97 million in Series C financing.
20 July 2020•1 min read
Antengene Corporation, a hematology and oncology-focused biopharmaceutical company, has raised $97 million in Series C financing.